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Abstract
Background: To examine potential differences in efficacy and safety of treatment with olanzapine in patients with
schizophrenia of white and black descent.
Methods: A post-hoc, pooled analysis of 6 randomized, double-blind trials in the treatment of schizophrenia,
schizophreniform disorder, or schizoaffective disorder compared white (N = 605) and black (N = 375) patients
treated with olanzapine (5 to 20 mg/day) for 24 to 28 weeks. Efficacy measurements included the Positive and
Negative Syndrome Scale (PANSS) total score; and positive, negative, and general psychopathology scores; and the
Clinical Global Impression of Severity (CGI-S) scores at 6 months. Safety measures included differences in the
frequencies of adverse events along with measures of extrapyramidal symptoms, weight, glucose, and lipid
changes over time.
Results: 51% of black patients and 45% of white patients experienced early study discontinuation (P = .133). Of
those who discontinued, significantly more white patients experienced psychiatric worsening (P = .002) while
significantly more black patients discontinued for reasons other than efficacy or tolerability (P = .014).
Discontinuation for intolerability was not different between groups (P = .320). For the estimated change in PANSS
total score over 6 months, there was no significant difference in efficacy between white and black patients (P =
.928), nor on the estimated PANSS positive (P = .435), negative (P = .756) or general psychopathology (P = .165)
scores. Overall, there was no significant difference in the change in CGI-S score between groups from baseline to
endpoint (P = .979). Weight change was not significantly different in white and black patients over 6 months (P =
.127). However, mean weight change was significantly greater in black versus white patients at Weeks 12 and 20
only (P = .028 and P = .026, respectively). Additionally, a significantly greater percentage of black patients
experienced clinically significant weight gain (≥7%) at anytime compared to white patients (36.1% vs. 30.4%, P =
.021). Changes across metabolic parameters (combined fasting and random lipids and glucose) were also not
significantly different between groups, with the exception of a greater categorical change in total cholesterol from
borderline to high among white subjects and a categorical change from normal to low in high density lipoprotein
(HDL) cholesterol among white males.
Conclusions: The findings did not demonstrate overall substantive differences in efficacy or safety between white
and black patients diagnosed with schizophrenia or related disorders treated with olanzapine. However, a
significantly greater percentage of black patients (36.1%) experienced clinically significant weight gain compared to
white patients (30.4%).
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Schizophrenia occurs universally and shows similar pat-
terns of symptoms across populations. The overall pre-
valence of schizophrenia is estimated to be between 1%
to 2% of the population, and the prevalence of major
psychotic disorders appears consistent across different
ethnic groups [1,2]. In the United States, the incidence
of schizophrenia also appears to be uniform across racial
and ethnic groups with the exception of higher rates of
schizophrenia among racial minorities living in larger
cities [2,3]. However, the diagnosis of schizophrenia has
been shown to be more frequent in black patients than
other ethnic groups [4-7]. Previous studies also suggest
that black patients may receive higher doses of antipsy-
chotics [3,8,9], are more likely to receive depot formula-
tion of antipsychotics [9-11], may be less likely to
receive a second generation antipsychotic (SGA) [12-15],
and have lower medication adherence [15].
Second generation antipsychotics have proven effective
in clinical trials and have experienced widespread use
for the treatment of schizophrenia. However, there is a
great variability in the response profiles of individual
patients. Recent research efforts have focused on tai-
lored therapeutics and identifying patients who will have
the optimal response with minimal adverse events either
before the treatment initiation or early in the course of
therapy. The field of genomics, proteomics, and metabo-
lomics are developing rapidly and may offer promise for
this purpose. Until then, patient subgroups may be iden-
tified at a broader level by baseline characteristics such
as metabolic status, duration of illness, symptom pat-
terns, and ethnicity. The interest in race and its influ-
ence on treatment outcomes is so great that the
National Institutes of Mental Health (NIMH) sponsored
an ongoing study, PAARTNERS (Project among African
Americans to explore risks for schizophrenia) seeking to
identify genetic polymorphisms that confer risk to schi-
zophrenia among black patients [16].
Race may also be an important demographic risk fac-
tor for metabolic abnormalities. The incidence of dia-
betes, dyslipidemias, and obesity are known to be more
prevalent among blacks in the general population. This
increased risk is also likely to extend to those suffering
from mental illness. However, the extent and nature of
this risk has yet to be adequately addressed.
To our knowledge, there have been no double-blind,
randomized controlled trials designed to compare anti-
psychotic differences among ethnic groups. The majority
of schizophrenia patients enrolled in clinical trials is of
white descent and separate results for ethnic minorities
are infrequently reported. Currently, minimal informa-
tion exists to help our understanding of any potential
ethnic differences in response and treatment-emergent
adverse events (TEAEs). Our study analyzed a large clin-
ical trial dataset of patients treated with olanzapine to
compare efficacy and safety characteristics between
black and white patients.
Methods
Study Design
Data were pooled from 6 similarly designed, rando-
mized, double-blind studies of olanzapine versus other
atypical antipsychotics (risperidone, quetiapine, ziprasi-
done, and aripiprazole) in the treatment of DSM-IV cri-
teria for schizophrenia, schizophreniform disorder, or
schizoaffective disorder [17-22]. For our selection cri-
teria, we chose studies based upon treatment duration
of no less than 6 months that contained at least one
double-blinded treatment arm of oral olanzapine. Eligi-
ble patients received olanzapine at doses between 5 to
20 mg. Studies were a mixture of both fixed dosed and
flexibly dosed designs. The 6 studies which met these
criteria were conducted from 1995 to 2003. Full details
of the study designs are reported in the published arti-
cles and briefly summarized in Table 1. Each individual
study was approved by the Ethics Committee from each
participating institution, patient confidentiality was not
breached, and the study was done in accordance to the
Declaration of Helsinki with written informed consent
obtained. We performed a posthoc analysis focused on
the treatment of olanzapine in white and black patients.
Assessments
Efficacy measures included the change in the Positive
and Negative Syndrome Scale (PANSS) total score,
PANSS positive, PANSS negative, and PANSS general
psychopathology scores over the 24- to 28- Week
period. Change in Clinical Global Impression severity
(CGI-S) score and time to all-cause discontinuation was
also evaluated. Safety measures included reporting of
TEAEs, categorical assessment of extrapyramidal symp-
toms (EPS), which was conducted using the Abnormal
Involuntary Movement Scale (AIMS)16, a 12-item scale
designed to record the occurrence of dyskinetic move-
ments, and used as the primary measure to assess the
incidence of tardive dyskinesia (TD). The Barnes Akathi-
sia Scale 18 was used to assess akathisia at baseline and
during treatment. The modified Simpson-Angus Scale
was used to measure treatment-emergent parkinsonism.
The definitions used for treatment emergent EPS based
on the above scales were AIMS: score ≥3i no n eo r
more body regions (Items 1-7) OR score = 2 in two or
more body regions (Items 1-7) for at least 1 month;
Barnes Akathisia global score of 2 or greater at any
postbaseline visit and a baseline score <2; Simpson
Angus >3 at any postbaseline visit and baseline
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(Items 1-7) OR score = 2 in two or more body regions
(Items 1-7) for at least 1 month. Glucose, lipid, and
weight changes were assessed over time. Fasting, ran-
dom, and combined laboratory outcomes were analyzed
as both categorical and continuous measures.
Statistical Analysis
Data from the 6 studies were pooled for these analyses.
Patients were analyzed on an intent-to treat (ITT) basis
for all analyses. Baseline characteristics were compared
between black and white patients by a Cochran-Mantel
Haenszel (CMH) test for categorical variables and by
analysis of variance for the continuous variables (both
adjusted by study). The proportion of patients who
experienced early study discontinuation, TEAEs, and
changes in EPS were compared between groups by a
CMH test, adjusting for protocol. Time to early discon-
tinuation was assessed by the Kaplan-Meier method and
log rank test. Analyses of the change from baseline in
efficacy rating scales (PANSS total, PANSS positive,
PANSS negative, PANSS general psychopathology, and
CGI-S) and weight were performed using a mixed-
model repeated measures (MMRM) analysis over 24
weeks. The models included the fixed, categorical,
effects of ethnic group, therapy week, baseline rating
score (weight), protocol, investigative site, and therapy
week by group interaction.
Differences in categorical lipid, glucose, and weight
values were compared between groups by a CMH test,
adjusting for protocol. Fasting triglyceride levels were
categorized as “normal”, “borderline”, “high”, and “extre-
mely high” based on the National Cholesterol Education
Project (NCEP) thresholds [23]. Categorical levels of
normal (<100 mg/dl), borderline, (≥100 mg/dl to <126
mg/dl) and high (≥126 mg/dl) for fasting glucose are
based on American Diabetic Association (ADA) criteria
[24]. Changes from baseline to endpoint in lipid and
glucose continuous measures were analyzed for within
group changes with a Wilcoxon-signed rank test and
between group differences were assessed with a ranked
analysis of variance (ANCOVA) model, controlling for
protocol and baseline value and using the method of
last observation carried forward (LOCF).
Patients with a baseline and at least one post-baseline
measure were included in all efficacy and laboratory
analyses. Adverse event analyses were performed on all
patients who took at least one dose of study drug. All
P-values were based on two-tailed tests with significance
level of .05 and ANCOVA models used Type III sum of
squares. To test for the optimal within subject covar-
iance matrix in each MMRM model, the following
structures were tested: unstructured, toeplitz, auto
regressive, and compound symmetric (both also includ-
ing the heterogeneous version). The optimal fit was
determined by Bayesian Information Criteria (BIC).
Results
Patient Characteristics
The pooled baseline demographics, psychiatric history,
and disease severity of patients are shown in Table 2.
Patients were chronically ill, diagnosed predominately
with schizophrenia, and exhibited an average illness
duration of about 16 years. Significant differences in
baseline characteristics between black and white patients
included: a significantly higher percentage of black
patients (86.6%) diagnosed with schizophrenia compared
to white patients (76.3%, P < .001), a significantly higher
Table 1 Studies Used in Analysis
Study Population Duration
(weeks)
Dose (mg/
day)
Inclusion Criteria Fasting
Labs
HGLB
17 Schizophrenia 28 10-20 (i) PANSS Total ≥75
(ii) PANSS Positive ≥4
(iii) CGI-S ≥4
Yes
HGJU
18 Schizophrenia, Schizoaffective with
Comorbid Depression
24 10-20 (i) MADRS Total ≥16
(ii) MADRS item #2 ≥4
Yes
HGJB
19 Schizophrenia, Schizoaffective with
negative Symptoms
24 10-20 (i) GAF ≤60
(ii) PANSS Negative ≥4 on at least 3 items or ≥5o n
at least 2 items
No
HGHJ
20 Schizophrenia 28 10-20 (i) BPRS ≥42
(ii) PANSS Positive ≥4
(iii) CGI-S ≥4
Yes
HGBG
21 Schizophrenia, Schizophreniform,
Schizoaffective
28 10-20 (i) BPRS ≥42 No
HGGN
22 Schizophrenia, Schizoaffective 52 5-20 (i) Illness duration ≥2 yrs
(ii) PANSS Positive≥4 on 2 items
(iii) BPRS ≥18
No
Abbreviations: PANSS = Positive and negative syndrome scale; CGI-S = Clinical global impression of severity; MADRS = Montgomery Asberg depression rating
scale; GAF = Global assessment of functioning; BPRS = Brief psychiatric rating scale.
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schizoaffective disorder compared to black patients
(13.4%, P < .001), a significantly higher percentage of
black patients (87.1%) whose geographical region was
the United States compared to white patients (69.1%,
P < .001), and a statistically significantly higher CGI-S
score for white patients (4.60, SD = .78) than black
patients (4.42, SD = .69, P = .002).
Patient Disposition
The percentage of patients completing the study and
reasons for discontinuation are shown in Figure 1. 51%
(191/375) of black patients discontinued treatment and
45% (272/605) of white patients discontinued treatment
with olanzapine for any reason over the 24-28 weeks
(P = .133). Of those who discontinued, significantly
more white patients discontinued due to psychiatric
worsening compared to black patients (P = .002) while
s i g n i f i c a n t l ym o r eb l a c kp a tients discontinued for
“other” reasons (e.g., patient decision, physician decision,
sponsor decision, noncompliance, lost to follow-up, and
criteria not met, P = .014). Discontinuations for medica-
tion intolerability were not different between groups
(P = .320). The mean modal dose of olanzapine for the
black patient group was 15.5 mg (SD = 4.3) and was
15.3 mg (SD = 4.2) for the white patient group. The
median exposure was 164 days for black patients and
166 days for white patients.
Efficacy
The primary efficacy measure was the estimated change
from baseline in the PANSS total score over 6 months.
At the end of treatment, the estimated mean reduction
was 27.0 points (SE = .80) for the white patient group
and 26.0 (SE = 1.10) for the black patient group. Over-
all, the reduction in the PANSS total score was not
found to be statistically significantly different between
groups (P = .928, Figure 2). Likewise, the overall esti-
mated mean changes from baseline in PANSS positive,
PANSS negative, and general psychopathology scores
were also not statistically different between groups (P =
.435, P = .756, P = .165, respectively).
For the CGI-S scale, at the end of treatment, the esti-
mated mean reductions were 1.34 points (SE = .05) for
the white patient group and 1.19 (SE = .07) for the
black patient group. Overall, there was no significant
difference in the change in CGI-S score between groups
from baseline to endpoint (P = .979). We did find, how-
ever, a statistically significant difference in the effect of
race with respect to time (P = .027) over the first 5
weeks. As seen in Figure 3, black patients show a more
rapid improvement compared to white patients over the
first five weeks of treatment with a statistical difference
seen at Week 2 (P < .05). No statistically significant dif-
ference between groups was seen for the remainder of
the analysis.
Given recent attention to the outcome of all-cause time
to discontinuation in the treatment of schizophrenia as a
proxy measure for treatment effectiveness (primary effi-
cacy measure in the CATIE trial), we performed a similar
analysis for this dataset. We found no statistically signifi-
cant difference in time to all-cause discontinuation
Table 2 Patient Demographics
Variable Black
Descent
White
Descent
P-
values
(N = 372) (N = 602)
Gender Male 264 (71.0%) 399 (66.3%) 0.132
Female 108 (29%) 203 (33.7%)
Age (yrs) Mean 39.96 39.79 0.514
SD 9.48 10.91
Median 40.49 39.85
Weight (kg) Mean 86.62 84.01 0.257
SD 21.93 20.73
Median 82.43 81.12
BMI (kg/m2) N = 362 N = 596 0.587
Mean 29.06 28.47
SD 6.95 6.51
Median 28.15 27.33
Geographic
Region
USA 324 (87%) 416 (69.1%) <0.001
Europe 4 (1.1%) 107 (17.8%
South America 37 (10%) 76 (12.6%)
Other 7 (1.9%) 3 (0.5%)
PANSS Total Mean 88.15 89.27 0.528
SD 15.45 17.66
Median 87.0 88
PANSS Positive Mean 21.31 21.08
SD 5.05 5.98
Median 21.5 21
Diagnosis Schizophrenia 322 (86.6%) 459 (76.3%) <0.001
Schizoaffective 50 (13.4%) 139 (23.1%) <0.001
Schizophreniform 0 (0%) 4 (0.7%) 0.298
CGI Score Mean N = 329 N = 505 0.002
SD 4.42 4.60
Median 0.69 0.78
4.00 4.00
# Previous
Episodes
N = 184 N = 341 0.296
Mean 8.53 7.07
SD 7.53 8.98
Median 6.0 4.0
Illness Duration N = 368 N = 600 0.547
Mean 16.83 15.92
SD 10.38 10.43
Median 15.45 15.17
Abbreviations: N = All randomized patients with at least one post-baseline
visit; SD = Standard Deviation; BMI = Body max index; PANSS = Positive and
negative syndromes scale; CGI = Clinical global impression.
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Page 4 of 11Figure 1 Patient disposition. Diagram summarizing patient disposition.
Figure 2 Estimated change in PANSS total score in olanzapine-
treated black and white patients over 24 weeks. Graph based
on MMRM Model including fixed terms baseline PANSS total score,
treatment week, protocol, investigator, race, and ethnic origin ×
treatment week. Race P-value = 0.93.
Figure 3 Estimated change in CGI-Severity score in olanzapine-
treated black and white patients over 24 weeks. A statistically
significant difference was found in the effect of race with respect to
time (P = 0.027). Black patients showed a more rapid improvement
in the first 5 weeks.
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versus not estimatable, respectively; P = .078).
Safety
The frequency of TEAEs occurring at ≥5% or any sta-
tistically significant events between groups are shown
in Table 3. The highest reported adverse events in
both groups were somnolence, headache, and weight
increased. Adverse events reported statistically signifi-
cantly more often in the white patient group compared
to the black patient group included: insomnia, tremor,
disturbance in attention, irritability, chills, and initial
insomnia. Adverse events reported statistically signifi-
cantly more often in the black patient group compared
to the white patient group included increased weight,
migraine, cyst, left ventricular hypertrophy, and
leukopenia.
No significant differences were found between black
and white patients who experienced categorical changes
at anytime on the Barnes Akasthisia Scale (a global
score ≥2; P = .226), the modified Simpson-Angus Scale
(a total score >3; P = .071), or AIMS (a score of ≥3o n
one or more body regions or a score of 2 in two or
more body regions for at least one month; P = 0.116).
Baseline data for weight and body mass index (BMI)
was not significantly different for black or white patients
(P = .257 and P = .587, respectively). The fixed effect
term for the estimated overall change from baseline
over the 24 weeks was not found to be statistically sig-
nificantly different between the two groups (P = .127,
Figure 4). However, we found a statistically significant
greater increase in weight change in black patients com-
pared to white patients at Weeks 12 and 20 (Week 12:
.83 kg, SE = .38, p = .028; Week 20: .87 kg, SE = .39,
P = .026). Additionally, the percentage of patients
experiencing clinically significant weight gain (defined as
an increase from baseline ≥7% at anytime) was 36.1% in
the black patient group compared to 30.4% in the white
patient group (P = .021)
Since one-half (3 of 6) of the studies required the col-
lection of blood samples in the fasting state, glucose
changes are reported separately as “fasting”, “random”
Table 3 Frequency of TEAEs Occurring at ≥5% or Any Statistically Significant Events
Event Term White
N = 600
N (%)
Black
N = 369
N (%)
Total
N = 969
N (%)
p-value* P = value**
Somnolence 88 (14.7) 52 (14.1) 140 (14.4) 0.851 0.792
Headache 76 (12.7) 62 (16.8) 138 (14.2) 0.088 0.057
Weight Increased 72 (12.0) 62 (16.8) 134 (13.8) 0.044 0.031
Insomnia 64 (10.7) 26 (7.0) 90 (9.3) 0.068 0.050
Anxiety 61 (10.2) 23 (6.2) 84 (8.7) 0.035 0.216
Dry Mouth 57 (9.5) 33 (8.9) 90 (9.3) 0.820 0.785
Nausea 47 (7.8) 27 (7.3) 74 (7.6) 0.804 0.858
Sedation 47 (7.8) 22 (6.0) 69 (7.1) 0.305 0.223
Increased Appetite 41 (6.8) 32 (8.7) 73 (7.5) 0.317 0.542
Depression 40 (6.7) 19 (5.1) 59 (6.1) 0.407 0.369
Fatigue 38 (6.3) 19 (5.1) 57 (5.9) 0.485 0.205
Neopharyngitits 36 (6.0) 15 (4.1) 51 (5.3) 0.236 0.165
Vomiting 35 (5.8) 13 (3.5) 48 (5.0) 0.127 0.154
Dizziness 32 (5.3) 20 (5.4) 52 (5.4) 1.000 0.791
Akathesia 31 (5.2) 11 (3.0) 42 (4.3) 0.143 0.230
Diarrhoea 31 (5.2) 24 (6.5) 55 (5.7) 0.394 0.375
Tremor 31 (5.2) 7 (1.9) 38 (3.9) 0.010 0.019
Disturbance in Attention 13 (2.2) 1 (0.3) 14 (1.4) 0.023 0.028
Irritability 12 (2.0) 0 (0.0) 12 (1.2) 0.005 0.012
Chills 8 (1.3) 0 (0.0) 8 (0.8) 0.027 0.032
Initial Insomnia 7 (1.2) 0 (0.0) 7 (0.7) 0.049 0.046
Migraine 1 (0.2) 4 (1.1) 5 (0.5) 0.073 0.033
Cyst 0 (0.0) 3 (0.8) 3 (0.3) 0.055 0.022
Left Ventricular Hypertrophy 0 (0.0) 2 (0.5) 2 (0.2) 0.145 0.017
Leukopenia 0 (0.0) 2 (0.5) 2 (0.2) 0.145 0.006
*Fisher Exact Test; **CMH Test adjusted for protocol.
Abbreviation: N = number of randomized patients who have taken at least 1 dose of study drug and have a post-baseline visit; TEAEs = treatment-emergent
adverse events.
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bined”, where we pooled the three non-fasting studies,
and the three fasting studies together. The mean change
from baseline to endpoint over 24 weeks in both the
fasting only studies and random only studies was not
significantly different between black and white patients
(P = .245 and .557, respectively). The within group
mean change in glucose from baseline in the fasting
only studies was 2.30 mg/dl (SD = 37.1, P = .689) in the
black group and 3.91 mg/dl in the white group (SD =
28.4, p = .033). The within group mean change in glu-
cose from baseline in the random only studies was 9.02
mg/dl (SD = 35.5, P = .179) in the black group and 4.75
mg/dl (SD = 38.1, P = .067) in the white group. We
found no significant difference between groups on the
percentage of patients that experienced an adverse cate-
gorical change in glucose levels at anytime during the
s t u d y( F i g u r e5 ) .W ea l s ol o o k e da tt h eo c c u r r e n c eo f
treatment-emergent diabetes (terms “Diabetes mellitus”
or “Type 2 diabetes mellitus”) and found no statistically
significant difference between groups (4 white patients
and 4 black patients, 0.7% versus 1.1%, P = 0.532).
Categorical changes in lipids are also reported sepa-
rately based upon protocol-specified fasting collection
methods. Fasting and random values were combined
across all six studies for total cholesterol and high-den-
sity lipoprotein (HDL) cholesterol while fasting only stu-
dies are reported for low density lipoprotein (LDL)
cholesterol and triglycerides. No statistically significant
differences were seen in any fasting values for LDL or
triglycerides between patients of either group (See
Figure 6). However, significantly more white patients
(59/135) had a categorical increase in fasting and
random cholesterol levels from borderline (≥200 mg/dl
and <240 mg/dl) to high (≥240 mg/dl) compared to
black patients (15/64; P = .019). Additionally, signifi-
cantly more white males (33/87) showed a decrease in
HDL cholesterol levels from normal (≥40 mg/dl) to low
(<40 mg/dl) compared to black males (24/105; P = .039).
Discussion
The results of this post-hoc analysis suggest similar
efficacy response for black and white patients with schi-
zophrenia treated with olanzapine. The reduction on
PANSS scores and PANSS subscale scores were similar
for both groups. We also found no overall differences
on changes in the CGI score and all-cause time to dis-
continuation. Our data is consistent with other studies
that did not show a difference between black and white
patients treated with antipsychotics [25,26]. The CATIE
(Clinical Antipsychotic Trials of Intervention Effective-
ness) study [27] recently reported preliminary results on
the effect of ethnicity in the treatment of schizophrenia
[25]. They reported no difference in all-cause time to
discontinuation and PANSS Total score between white,
black, and Hispanic subgroups. Another study looked at
the impact of race on the efficacy and safety of long-act-
ing risperidone compared to placebo [26]. These results
showed there was no effect of race on the improvement
of PANSS total scores from baseline to endpoint. In
contrast, one study conducted in Africa did show a
greater reduction in PANSS total score by mixed des-
cent and black patients compared to white patients [28].
While one potential explanation of this finding could be
described by significant differences in baseline PANSS
scores, the divergence to our results and other studies is
worth noting.
As overall discontinuation rates did not differ between
groups, significantly more white patients (18%) discon-
tinued due to psychiatric worsening than black patients
(9%). While the number of patients in this sample was
small, this may warrant further discussion. Since PANSS
total improvements were similar between groups, the
discontinuation due to psychiatric worsening in the
white subgroup is counter-intuitive. This may be
explained by the variability in individual responses that
may not be captured in our larger dataset and analysis
methods. The largest percentage of discontinuations
from the studies was due to reasons other than poor
response/psychiatric worsening and medication intoler-
ability. In fact, a higher percentage of black patients dis-
continued from the study compared to white patients
due to these other reasons (patient decision, physician
decision, sponsor decision, noncompliance, lost to fol-
low-up, and criteria not met). This is fairly consistent
with the overall CATIE study results, where the largest
percentages of treatment discontinuations were due to
Figure 4 Estimated change in weight in olanzapine-treated
black and white patients over 24 weeks. Graph based on MMRM
Model including fixed terms baseline weight, treatment week,
protocol, investigator, race, and ethnic origin × treatment week.
Race P-value = 0.13.
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other reasons effect individual treatment outcome may
give additional insight into the treatment approach to
schizophrenia.
A recent study suggested there may be a higher pre-
dictability of weight gain with clozapine in black patients
[29]. In our analysis, a statistically significant difference
in weight change was found in the black patient group
compared to the white patient group only at Weeks 12
and 20, but the numerical difference between the two
groups was less than 2 pounds. Overall baseline to end-
point changes in weight was not statistically significant
between groups. However, a statistically higher percen-
tage of black patients (16.8%) versus white patients
(12.0%) reported “increased weight gain” as a treatment
emergent adverse event. Likewise, a statistically signifi-
cantly greater number of black patients reported catego-
rical clinically significant weight gain of ≥7% anytime
during the study. Therefore, while overall mean weight
change throughout the studies was not different, there is
some evidence in our study to suggest that black patients
may be at greater risk for weight changes.
Research has also suggested that glucose, lipid, and
overall metabolic abnormalities may be higher with sec-
ond generation antipsychotics in black patients [30-33].
The CATIE study showed that, at baseline, black
patients had a higher incidence of dyslipidemias. Other
studies have evaluated the ethnic differences with medi-
cation on visceral adiposity, insulin resistance, glucose,
and cholesterol [34-36]. These studies concluded that
ethnic minorities may have a greater risk of treatment-
emergent metabolic adverse events which may differ
depending on the medication prescribed. A recent
review article looking at ethnic differences in the risks
of adverse events in treating psychoses and depression
showed a higher relative risk for hyperglycemia in black
patients compared to non-black patients and a higher
relative risk for diabetes mellitus in non-white patients
compared to white patients. [37]. Unlike our analysis,
this study included patients with depression. In our
study, no significant differences were seen between
groups in both fasting and random glucose concentra-
tions, as well as treatment emergent diabetes. There
was, however, a statistically significant within-group
Figure 5 Percentage of patients experiencing adverse categorical glucose changes at anytime.
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white subgroup. Within group differences were not seen
in the black subgroup. Additional long-term data are
needed to better understand the potential effect of race
on glucose levels with medication treatment.
For lipids, we also did not find consistent differences
between groups, with a couple of exceptions. In the
combined fasting and random cholesterol analysis, cate-
gorical change from borderline to high total cholesterol
was greater in the white subgroup compared to the
black subgroup. Combined fasting and random HDL
cholesterol changes from normal to low in the white
male patients was also statistically significant compared
to black male patients. These statistical changes for the
white subgroup, although a result of combined random
and fasting blood testing, differ from results of other
studies. [34-36].
Our study did not show any significant differences
between groups on measures of EPS. Earlier studies
have identified race as a risk factor for the development
of TD and pointed that race may be a factor in predict-
ing a poor course of TD. This is in contrast to the
Figure 6 Treatment-emergent categorical lipid changes.
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Page 9 of 11CATIE trial analysis, where white patients had worse
outcomes on the Simpson-Angus Scale (P <.001), and
Barnes Akathisia Scale (P < .001) compared to the black
patient group. More data may be needed to confirm the
potential effect of race on EPS and TD outcomes.
While we did not find significant differences in overall
outcomes between black and white patients, the impor-
tance of individual variability in antipsychotic efficacy
and tolerability must be considered. We did not look at
genetic differences; however, there is a growing body of
research on genetic susceptibility to schizophrenia, med-
ication treatment, and the potential effect of race. This
data thus far have been fairly inconclusive [38-41].
A recent candidate gene association analysis with risper-
idone showed a potential genetic link to poor response
in white patients versus black patients, but sample size
was small and requires replication [42]. Patients with
schizophrenia are a highly diverse population and a clin-
ician must be sensitive to the individual differences that
exist and may not be seen in a dataset such as ours.
One important limitation to this study is that this was a
pooled, posthoc analysis, and therefore, it was not pro-
spectively powered to specifically assess efficacy compari-
sons between black and white patients treated with
schizophrenia However, we attempted to overcome this
limitation by combining six similarly designed studies and
producing a large dataset for analysis. In addition, the
results are adjusted for the six separate studies with “pro-
tocol” used as a term in the MMRM model. The total
number of black patients in this clinical trial dataset is
impressive given the small amount of published informa-
tion on the potential effect of race on treatment outcomes
i ns c h i z o p h r e n i a .W h i l et h eC A T I Es t u d yh a dal a r g e
number of black patients (n = 513 across all treatment
groups) in their recent analysis looking at ethnic variability
in response and adverse events to antipsychotics, our data-
set for olanzapine-treated black patients (n = 375) is the
largest for a single drug treatment, to our knowledge.
Another limitation is the focus on only patients of
black descent, primarily from the United States. Due to
the small number of patients in our studies representing
Hispanic, Asian, and other minorities, comparisons
among these ethnic subgroups were not possible, but
are also needed in the literature.
Within our analysis, there is a lack of information on
prior exposure to atypical antipsychotics. Since these
were comparative trials and patients suffered from
chronic schizophrenia, it is likely that there were prior
medication exposures which could affect their baseline
values on weight and glucose. Therefore, our results
must be interpreted with respect to prior exposures.
There was a high drop-out rate in our analysis with
almost half of patients discontinuing the study prior to
24-28 weeks. To account for this in the analysis, we
used MMRM analysis for efficacy (PANNS and CGI-S)
and weight. Last observation carried forward was used
to analyze lipids, glucose, EPS, and weight. MMRM
could not be performed on lipids, glucose, and EPS
since these measures were not collected at every visit in
each study included in the analysis.
We also performed many comparisons in this analysis
and did no type of formal statistical adjustment for this
fact. For example, while black patients had a statistically
significantly greater baseline CGI-S score than white
patients, we felt this difference was not clinically signifi-
cant to warrant a statistical adjustment. For the efficacy
endpoints, we choose only a selected few measures that
we felt were clinically significant. For the safety mea-
sures, we ignored multiplicity as a conservative measure
in order to evaluate any potential safety signals which
may be missed by lowering the P-value.
Conclusion
The present analysis suggests that olanzapine is equally
efficacious in black and white patients in the treatment
of schizophrenia. Prospective studies are necessary to
confirm if black and white patients may have different
response patterns to antipsychotics, which would help
clinicians tailor antipsychotic therapies accordingly.
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